Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

在生物制药板块面临挑战的背景下，Cassava Sciences Inc. (SAVA)的股价已跌至52周低点，触及3.35美元。根据 InvestingPro 的数据，该公司保持着3.55的健康流动比率，且现金多于债务，尽管技术指标显示该股票目前处于超卖状态。作为神经退行性疾病药物研发的前沿公司，Cassava Sciences的股票受到了更广泛的市场逆风和对其管线进展的特定担忧的打击。过去一年 ...

Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

阿尔茨海默症其新药研发失败率高达99.6%。昨天我们分享了两家失败的药物Simufilam和AL002，其 针对的靶点较为新颖。今日我们就其靶点和数据进行分析。

Cassava Sciences’ ReThink-ALZ phase 3 study of simufilam in mild-to-moderate AD fails to meet co-primary endpoints: Austin, Texas Wednesday, November 27, 2024, 18:00 Hrs [IST] C ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences announced that the phase 3 trial of its Alzheimer's drug, simufilam, did not meet its primary endpoints.

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...